Biological E. Limited (BE) has achieved a major regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for Dalbavancin for Injection, 500 mg per vial (single-dose vial). The product is the generic equivalent of DALVANCE® (dalbavancin) for injection, a widely used antibiotic for treating serious bacterial infections.
With this approval, Biological E becomes the first Indian pharmaceutical company to receive U.S. FDA approval for generic Dalbavancin, underscoring the company's growing expertise in the development and manufacturing of complex sterile injectable products for international markets.
Dalbavancin is a long-acting lipoglycopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including certain strains of Staphylococcus aureus. The approval expands access to a more affordable treatment option for patients in the United States while supporting healthcare systems with cost-effective alternatives.
The achievement highlights Biological E's strong regulatory capabilities and commitment to delivering high-quality medicines that meet stringent global standards. The approval also strengthens the company's presence in the U.S. generic pharmaceutical market and reflects its continued investment in advanced manufacturing technologies and product development.
In a statement, the company described the approval as a significant step toward its mission of expanding access to affordable healthcare solutions worldwide. The milestone further demonstrates Biological E's ability to successfully navigate complex regulatory pathways and bring critical injectable therapies to global patients.
